Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
暂无分享,去创建一个
R. Fonseca | D. Dingli | A. Dispenzieri | Shaji K. Kumar | S. Rajkumar | C. Reeder | V. Roy | M. Gertz | J. Lust | T. Witzig | M. Lacy | B. Laplant | S. Hayman | F. Buadi | S. Zeldenrust | J. Mikhael | S. Russell | K. Laumann | R. Hall | A. Stewart | P. Bergsagel
[1] M. Skinner,et al. Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial , 2012 .
[2] P. L. Bergsagel,et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. , 2012, Blood.
[3] B. Pégourié,et al. High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02 , 2011 .
[4] D. Esseltine,et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. , 2011, Blood.
[5] D. Seldin,et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. , 2010, Blood.
[6] P. L. Bergsagel,et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. , 2010, Blood.
[7] M. Dimopoulos,et al. Validation of the Criteria of Response to Treatment In AL Amyloidosis. , 2010 .
[8] A. Foli,et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. , 2010, Blood.
[9] D. Dingli,et al. Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs , 2010, American journal of hematology.
[10] P. L. Bergsagel,et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) , 2010, Leukemia.
[11] M. Dimopoulos,et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Salles,et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. , 2009, Blood.
[13] A. Foli,et al. A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis. , 2009 .
[14] P. Hawkins,et al. Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment. , 2009 .
[15] D. Dingli,et al. A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis. , 2009 .
[16] P. L. Bergsagel,et al. Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM). , 2009 .
[17] D. Reece,et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.
[18] P. Hawkins,et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease , 2008, Haematologica.
[19] M. Dimopoulos,et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.
[20] G. Merlini,et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. , 2007, Blood.
[21] P. Hawkins,et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. , 2007, Blood.
[22] A. Dispenzieri,et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. , 2007, Blood.
[23] A. Dispenzieri,et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. , 2006, Archives of dermatology.
[24] G. Merlini,et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. , 2006, Blood.
[25] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[26] G. Merlini,et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). , 2005, Blood.
[27] T. Therneau,et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.
[28] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Falk,et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. , 2003, Clinical lymphoma.
[31] R. Fonseca,et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[32] John O'Quigley,et al. An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .
[33] T. Therneau,et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.
[34] R. Falk,et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. , 1996, Blood.
[35] A. Foli,et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide , 2011, Annals of Hematology.
[36] M. Skinner,et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. , 2007, Blood.
[37] It Istituto Superiore di Sanit,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .